The effects of add-on therapy of DPP4 inhibitor, Vildagliptin, on glucose control and diabetic complication in type 2 diabetes mellitus treated with insulin administratio
- Conditions
- Type 2 diabetes mellitus
- Registration Number
- JPRN-UMIN000010176
- Lead Sponsor
- Shimane University Faculty of Medicine
- Brief Summary
The baseline characteristics of subjects, including age, dose of insulin injections, or HbA1c levels, did not differ between the two groups. In the vildagliptin group, HbA1c levels significantly decreased and the significance of HbA1c reduction was maintained for 24 months (from 8.0% to 7.4%, p<0.05, at the end of observational period). In addition, the dose and number of insulin injections significantly reduced (-5.6 units, p<0.01, and -0.9 times, p<0.001). However, these parameters were unchanged in the control group. The number of patients who experienced three or more episodes of hypoglycemia per year was significantly lower in the vildagliptin group (n=4) than in the control group (n=11) (odds ratio, 0.28; 95% confidence interval, 0.08-0.97; p<0.05).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 400
Not provided
type 1 diabetes mellitus, severe liver injury, heart failure, pancreatitis, ileus
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Plasma glucose, HbA1c, diabetic retinopathy, diabetic nephropathy, cardiovascular disease, cerebral infarction, fracture, cancer
- Secondary Outcome Measures
Name Time Method